Day 2

IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.

solaci
solaci
606
0

 IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock. 

IABP-shock-artigo

Holger Thiele
2012-08-26

Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

Previous article
PROTECT: A comparison of thrombosis incidence between the drug-eluting stents sirolimus and zotarolimus.
Next article
FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.
solaci
solaci

More articles by this author

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

solaci - 0
Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high,...

GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.

solaci - 0
Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration...

GARY: German Aortic Valve Registry.

solaci - 0
Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant...

FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.

solaci - 0
Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 2

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers....
solaci -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Dr. Omar Tupayachi - 0
Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Dr. Juan Manuel Pérez - 0
Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Dr. Juan Manuel Pérez - 0
Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...